A Framework for the Use and Likelihood of Regulatory Acceptance of Single-Arm Trials
Therapeutic Innovation & Regulatory Science · 2024
DOI: 10.1007/s43441-024-00693-8 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Therapeutic Innovation & Regulatory Science, 2024. Verfasst von Disha Subramaniam und 5 weiteren Autor:innen. Beteiligte Einrichtung: Real World Evidence and Patient Outcomes, CERobs Consulting, Wrightsville Beach, NC, USA. dsubramaniam@unc.edu. Hauptthemen laut MEDLINE: Drug Approval, United States Food and Drug Administration, Clinical Trials as Topic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceuticals U.S.A..
Abstract (Originalsprache)
Background
Single-arm clinical trials (SAT) are common in drug and biologic submissions for rare or life-threatening conditions, especially when no therapeutic options exist. External control arms (ECAs) improve interpretation of SATs but pose methodological and regulatory challenges.
Objective
Through narrative reviews and expert input, we developed a framework for considerations that might influence regulatory use and likelihood of regulatory acceptance of an SAT, identifying non-oncology first indication approvals as an area of interest. We systematically analyzed FDA and EMA approvals using SATs as pivotal evidence. The framework guided outcome abstraction on regulatory responses.
Methods
We examined all non-oncology FDA and EMA drug and biologic approvals for first indications from 2019 to 2022 to identify those with SAT as pivotal safety or efficacy evidence. We abstracted outcomes, key study design features, regulator responses to SAT and (where applicable) ECA design, and product label content.
Results
Among 20 SAT-based FDA approvals and 17 SAT-based EMA approvals, most common indications were progressive rare diseases with high unmet need/limited therapeutic options and a natural history without spontaneous improvement. Of the types of comparators, most were natural history cohorts (45% FDA; 47% EMA) and baseline controls (40% FDA; 47% EMA). Common critiques were of non-contemporaneous ECAs, subjective endpoints, and baseline covariate imbalance between arms.
Conclusion
Based on recent FDA and EMA approvals, the likelihood of regulatory success for SATs with ECAs depends on many design, analytic, and data quality considerations. Our framework is useful in early drug development when considering SAT strategies for evidence generation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Real World Evidence and Patient Outcomes, CERobs Consulting, Wrightsville Beach, NC, USA. dsubramaniam@unc.edu.
- Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. dsubramaniam@unc.edu.
- Takeda Pharmaceuticals, Cambridge, MA, USA.
- Real World Evidence and Patient Outcomes, CERobs Consulting, Wrightsville Beach, NC, USA.
- Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Förderung
- Takeda Pharmaceuticals U.S.A.
Zitieren
APA
Subramaniam, D., Anderson-Smits, C., Rubinstein, R., Thai, S. T., Purcell, R., & Girman, C. (2024). A Framework for the Use and Likelihood of Regulatory Acceptance of Single-Arm Trials. Therapeutic Innovation & Regulatory Science. https://doi.org/10.1007/s43441-024-00693-8
Vancouver
Subramaniam D, Anderson-Smits C, Rubinstein R, Thai ST, Purcell R, Girman C. A Framework for the Use and Likelihood of Regulatory Acceptance of Single-Arm Trials. Therapeutic Innovation & Regulatory Science. 2024. doi:10.1007/s43441-024-00693-8
BibTeX
@article{Subramaniam2024,
author = {Subramaniam, Disha and Anderson-Smits, Colin and Rubinstein, Rebecca and Thai, Sydney T and Purcell, Rose and Girman, Cynthia},
title = {A Framework for the Use and Likelihood of Regulatory Acceptance of Single-Arm Trials},
journal = {Therapeutic Innovation & Regulatory Science},
year = {2024},
doi = {10.1007/s43441-024-00693-8}
}
EUVIMED